Meitheal Pharmaceuticals has Docetaxel Injection, USP Now Available

Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Docetaxel Injection, USP, 80 mg per 8 mL (10 mg per mL) in a multi-dose vial and Docetaxel Injection, USP, 160 mg per 16 mL (10 mg per mL) vial in a multi-dose vial.

Meitheal will offer Docetaxel Injection, USP in a pack of 1 vial for both presentations.


Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer link.

Learn more about who we are and what we do at